ESTRO PT 2018

Strategies of RTOG-1308:

a) The prescribed dose for this study is 70 Gy. The study is designed to allow lower doses in situations for which critical structure constraints cannot be met. After randomization the patient’s dose will be individualized to the highest achievable dose (within normal tissue organs- at-risk constraints) between 60-70 Gy; b) Cross-over from protons to photons not permissable. c) The protocol will maintain strict organs-at-risk constraints for this trial; d) The protocol will perform preliminary quality assurance review as patients are entered on the trial to monitor dose prescriptions and dose/contouring compliance.